Trial Profile
Phase II Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Feb 2022 Planned End Date changed from 1 Feb 2026 to 28 Feb 2026.
- 04 Feb 2022 Planned primary completion date changed from 1 Feb 2025 to 28 Feb 2025.
- 04 Feb 2022 Status changed from recruiting to active, no longer recruiting.